Surgery – Blood drawn and replaced or treated and returned to body – Constituent removed from blood and remainder returned to body
Patent
1996-06-03
1998-03-24
Kulkosky, P. F.
Surgery
Blood drawn and replaced or treated and returned to body
Constituent removed from blood and remainder returned to body
604 5, 424489, 422 44, A61K 3514, A61M 114, A61M 3700
Patent
active
057307130
ABSTRACT:
This invention provides a composition, device and method for the removal of selected factors, such as cytokines or pharmaceuticals, from a substance such as whole blood or plasma. Advantageously, the invention provides for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood. Pharmaceuticals can be removed from an individual's whole blood or plasma, such as for use in treating drug overdosage.
REFERENCES:
patent: 3522346 (1970-07-01), Chang
patent: 3607857 (1971-09-01), Nelson
patent: 3998946 (1976-12-01), Condie et al.
patent: 4006059 (1977-02-01), Butler
patent: 4059685 (1977-11-01), Johnson
patent: 4072566 (1978-02-01), Lynn
patent: 4102746 (1978-07-01), Goldberg
patent: 4420395 (1983-12-01), Tanihara et al.
patent: 4472303 (1984-09-01), Tanihara et al.
patent: 4728432 (1988-03-01), Sugiyama et al.
patent: 4748121 (1988-05-01), Beaver et al.
patent: 4787974 (1988-11-01), Ambrus et al.
patent: 4861707 (1989-08-01), Balint, Jr. et al.
patent: 4865841 (1989-09-01), Balint, Jr.
patent: 4883765 (1989-11-01), Tamir et al.
patent: 4963265 (1990-10-01), Okarma et al.
patent: 5022988 (1991-06-01), Okarma et al.
patent: 5041079 (1991-08-01), Takashima et al.
patent: 5294401 (1994-03-01), Hagiwara
patent: 5421815 (1995-06-01), Noguchi et al.
patent: 5437861 (1995-08-01), Okarma et al.
patent: 5523096 (1996-06-01), Okarma et al.
Lee et al., Hemofiltration Removes Toxic Mediators and Prolongs Survival in Staphylococcus Aureus Sepsis Acute Lung Injury, Am. Rev. Respir. Dis. 141:A140 (1990).
Matson et al., Continuous Arteriovenous Hemofiltration (CAVH) therapy for Sepsis-Induced Acute Lung Injury in Immature Swine, FASEB J. 4(4):A953 (1990).
Molines et al., Formation of C5a During Cardiopulmonary Bypas: Inhibition by Precoating With Heparin, Ann. Throrac. Surg. (1991) 52:92-97.
Tamiya et al., Significance of the concentrated red cell and albumin priming method with particular reference to anaphylatoxin generation, J. Thorcic & Cardiovascular Surg. (1992) 103(1):78-86.
Murugavel, In Vitro Studies of the Efficacy of Reversed Phase Silica Gel as a Sorbent for Hemo- and Plasmaperfusion, J. Toxicol (1992) 30(1):69-82.
Bol'shakov et al., Protective Effect of Anti-staphylococcal Immunosorbent on the Phenotype of Lymphocyte Membrane in Diffuse Staphylococcus-Pseudomonas Peritonitis, Vestn. Akad. Med. Nauk, SSSR 7:36-40, (1991).
Lin et al., Laboratory Evaluation of Hemoperfusion Adsorptive Resin Column for the Treatment of Sepsis and Septic Shock, Abst. American Society for Aphersis, 13th Annual Mtg. (1992).
Blankenship John
Elkalay Mohammad A.
Lin Abraham T.
Okarma Thomas B.
Kulkosky P. F.
Rhone-Poulenc Rorer Pharmaceuticals Inc.
LandOfFree
Removal of selected factors from whole blood or its components does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Removal of selected factors from whole blood or its components, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Removal of selected factors from whole blood or its components will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2285115